# Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

> **NCT04885907** · PHASE4 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 120 (actual)

## Conditions studied

- Vaccine Response Impaired
- Immune Suppression
- Covid19

## Interventions

- **BIOLOGICAL:** mRNA-1273 vaccine
- **OTHER:** Normal Saline Placebo

## Key facts

- **NCT ID:** NCT04885907
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-25
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04885907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04885907, "Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04885907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*